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IFNcIn vivo vaccination studies are conventionally conducted in a single mouse strain with results, only
reflecting responses to a single immunogenetic background. We decided to examine the immune
response to an HIV transgene (gag, pol and nef fusion protein) in 3 strains of mice (CBA, C57BL/6 and
BALB/c) to determine the spectrum of responses and in addition to determine whether the serotype of
the adenoviral vector used (ChAd3 and ChAd63) impacted the outcome of response. Our results demon-
strated that all three strains of mice responded to the transgene and that the magnitude of responses
were different between the strains. The C57BL/6 strain showed the lowest range of responses compared
to the other strains and, very few responses were seen to the same peptide pool in all three strains of
mice. In CBA and BALB/c mice there were significant differences in IFNc production dependent on the
adenoviral vector used. Our results suggest that employing a single strain of mouse may underestimate
the efficacy and efficiency of vaccine products.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The development of a prophylactic HIV viral vector vaccine has
remained challenging due to the absence of immunogenic
responses to some viral vectors and the presence of pre-existing
neutralising antibody immunity to human adenovirus vectors in
a large proportion of the human population. The isolation of new
vectors that are able to induce immune responses to the same level
as those seen with human adenoviruses and with low sero-
prevalance of neutralising antibodies in humans, have contributed
to the progress of vector vaccine choice [1–3] though some of these
vectors do not mount efficient immune response in animal models
[4].
It is known that immune responses to the Gag, Pol and/or Nef
proteins of HIV do offer some protection against the virus in sev-
eral animal models [5–8]. Most in vivo vaccination studies employ
the use of a single mouse strain, with the C57BL/6 strain being pre-
dominantly used for HIV vaccine studies. We have previously
shown that two viral vectors, chimpanzee adenoviruses (ChAd) 3
and 63 bearing a mosaic transgene formed from parts of HIV gag,pol and nef genes, were able to induce immune responses in
C57BL/6 mice [9]. As with most mouse vaccination studies, it is dif-
ficult to use these results to predict the efficacy of the vaccine in
humans due to the limited immunogenetic variation seen in inbred
murine lab strains [10]. In our hands, we found that C57BL/6
responses to our HIV transgene were narrow for both vectors [9].
To compensate for the lack of genetic variability in our animal
model, we decided to compare the immune response to our HIV
transgene in 3 strains of mice, each representing a different haplo-
type. We chose the CBA strain, which is k restricted, the C57BL/6
strain which is b restricted and the BALB/c strain which is d
restricted. In addition to comparing the immune responses to our
HIV transgene of interest, this study also provided the opportunity
to determine if there were any differences in responses to the vec-
tor employed in the different strains of mice.
2. Materials and methods
2.1. Mice
CBA, BALB/c and C57BL/6 mice were purchased from Charles
River (UK); 6–8 week old females were used. Mice were injected
subcutaneously with either 1  108 IU of ChAd3 or 1  109 IU of
S. Herath et al. / Vaccine 34 (2016) 4378–4385 4379ChAd63. Mice were sacrificed 7 days post vaccination. All in vivo
procedures were performed in accordance with Royal Holloway
and Home Office regulations for animal experimentation.2.2. Spleen cell isolation
Splenocyte suspensions were obtained using a glass homogeni-
ser (Fisher) with RPMI containing 10% FBS, 100 IU/ml penicillin and
0.1 mg/ml streptomycin (Gibco). Cells were treated with red cell
lysis buffer as directed (Sigma-Aldrich). Live cells were counted
using Trypan blue exclusion.2.3. Peptides
Individual HIV-ZM96 Gag overlapping peptides (15-mers over-
lapping by 10 amino acids) were provided by NIBSC, UK and dis-
solved in water. Reconstituted individual overlapping peptides
for HIV-ZM96 Pol 50, Nef and Pol 30 were provided by the Interna-
tional Aids Vaccine Initiative (IAVI). The peptides were pooled into
peptide pool matrices and used at a concentration of 1 lg/ml as
previously described [9].2.4. IFNc ELISpot
HIV specific IFNc T cell responses were determined by restimu-
lation of splenocytes with peptides and quantified by anti-mouse
IFNc ELISpot (Mabtech AB, Sweden) as previously described [9].
Plates were read using an AID ELISpot reader (AutoImmun Diag-
nostika, Germany).2.5. Statistical analysis
Data were analysed with GraphPad Prism V6.04 using Multiple
parametric independent-measures T tests. Significance was
reached at p < 0.05.3. Results
In our previous work we showed responses in the C57BL/6 mice
to an HIV transgene containing elements of gag, pol and nef genes
(GPN) delivered by two vectors; ChAd3 and ChAd63 [9]. Our results
showed ChAd3-GPN was more immunogenic than ChAd63-GPN
and that to produce equivalent IFNc ELISPOT responses a higher
dose of ChAd63-GPN was required. Therefore, in this study differ-
ent mouse strains were immunised with either 1  108 IU of
ChAd3-GPN or 1  109 IU ChAd63-GPN to determine whether
there were differences in responses to the transgenes and vectors.3.1. Strain dependent Gag responses
It is well documented that protective responses against HIV are
Gag dominated [5,7] and so we determined the immune response
to the gag transgene in CBA, C57BL/6 and BALB/c strains of mice
(Fig. 1). The magnitude and breadth of IFNc responses seen in
CBA (Fig. 1A) and BALB/c (Fig. 1C) mice were greater than those
of C57BL/6 mice (Fig. 1B). Unlike C57BL/6 mice where we saw
responses to 7 out of 14 Gag peptide pools, CBA mice responded
to 13 out of 14 peptide pools and BALB/c mice responded to 10
out of 14 peptide pools. In addition, some responses were signifi-
cantly higher in ChAd63 vaccinated animals compared to ChAd3
vaccinated animals in CBA (peptide pools 3, 5 and 8) and BALB/c
strains of mice (peptide pools 4 and 12) (Fig. 1A and C).3.2. No correlation between predicted and measured responses
To assess whether the magnitude and breadth of the response
were due to more efficient epitope binding by some strains of mice,
we investigated the binding prediction (http://www.mpiib-berlin.
mpg.de/mpiib-cgi/MAPPP/binding) of the transgenes for H-2K
restriction and chose scores above 16 as a cut off for efficient bind-
ing (Table 1). The results predict that BALB/c mice have the highest
number of epitopes binding for all the transgenes followed by CBA
mice and C57BL/6 mice. However, BALB/c mice did not have the
highest frequency of responses to Gag as predicted (Fig. 1C). We
also determined whether the results in Table 1 matched the
in vivo data for the pol 50, nef and pol 30 parts of the GPN transgene
by assessing the immune responses in both ChAd3 and ChAd63
vaccinated CBA and BALB/c strains of mice. Responses to the mega-
pools (all peptides for the protein present in a single pool) of the
aforementioned transgenes were studied and our results showed
that there were significantly higher responses to the Pol 50 and
Pol 30 megapools in CBA and BALB/c strains of mice compared to
C57BL/6 mice with both vaccinated vectors (Fig. 2). There were
no responses to Nef in CBA mice with either vector despite the
binding prediction, but there were responses to Nef in BALB/c mice
with both vectors.
3.3. Transgene and vector responses differ between animal strains
To investigate further the breadth and magnitude of the
responses in the different strains, we vaccinated the strains of mice
with either vector and analysed the IFNc response to smaller pep-
tide pools for each transgene element. With respect to Pol 50, the
C57BL/6 strain responded to 4 peptide pools with both vectors
(pools 4, 8, 14 and 15) and one peptide pool with ChAd63 (pool
13) out of 18 peptide pools (Fig. 3B), CBA mice responded to 8 pep-
tide pools with both vectors (pools 1, 3, 7, 12, 13, 16, 17, and 18;
Fig. 3A) and BALB/c mice responded to 6 peptide pools with both
vectors (pools 4, 5, 14, 15, 17, and 18) and one peptide pool with
ChAd63 (pool 2) and one with ChAd3 (pool 7; Fig. 3C).
Furthermore, in the CBA strain of mice, there were some signif-
icant differences in responses to peptide pools between ChAd3 and
ChAd63 vaccinated animals (Fig. 3A; peptide pools 3, 7 and 16).
When we analysed the Pol 30, we found that compared to the
C57BL/6 strain, which responded to 3 out of 20 peptide pools with
either vector vaccination (Fig. 4B), CBA mice responded to 8 pep-
tide pools with either vector vaccination (pools 2, 6, 7, 10, 14, 15,
17, and 18) and 4 peptide pools with only ChAd3 vaccination
(pools 1, 9, 19, and 20; Fig. 4A), and BALB/c mice responded to 9
peptide pools with either vector vaccination (pools 2, 3, 6, 9, 11,
12, 13, 18 and 19) and 6 peptide pools with only ChAd3 vaccination
(pools 1, 5, 7, 10, 14 and 16; Fig. 4C). Again, we saw that in the CBA
strain of mice, there were significant differences in response to
some peptide pools between ChAd3 and ChAd63 vaccinated ani-
mals (Fig. 4A; peptide pools 2, 7, 14, 17 and 18).
With respect to Nef, BALB/c mice responded to 5 out of 14 pep-
tide pools with either vector vaccination (pools 4, 5, 8, 10 and 13)
and 2 peptide pools with only ChAd3 vaccination (pools 6 and 14;
Fig. 4D). Our previous work showed that C57BL/6 mice responded
to 3 out of 14 peptide pools to Nef with only the ChAd3 vaccina-
tion. No responses were seen in CBA mice to the Nef peptide pools
(data not shown).
3.4. Heat map of IFNc responses to all peptide pools in different strains
of mice
We collated the data into a heat map to compare all the
responses between the strains of mice and vector vaccinations
(Fig. 5). With Gag, responses to 3 peptide pools were common to
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Fig. 1. IFNc responses to Gag peptide pools in different strains of mice. CBA (A), C57BL/6 (B) and BALB/c (C) mice were vaccinated with either 1  108 IU of either ChAd3-GPN
(black bar) or 1  109 IU ChAd63-GPN (grey bar). Splenocytes were harvested and stimulated with the indicated gag peptide pools. IFNc production was determined by
ELISpot and the graphs represent the mean of 6 mice ± SD from 2 separate experiments. *p < 0.05.
4380 S. Herath et al. / Vaccine 34 (2016) 4378–4385all three strains of mice with both vector vaccinations (Fig. 5A;
peptide pools 5, 9 and 10), and 2 common peptide pools were
observed to Pol 30 (Fig. 5C; peptide pools 6 and 18). There were
no common peptide pools to Pol 5’ and Nef (Fig. 5B and D). The
map also showed that there were differing magnitudes of response
to some common peptide pools between the strains of mice and
that the C57BL/6 strain of mouse had the least diverse response
to Gag, Pol 50, Pol 30 and Nef peptides.
Taken together these results showed that there are differing
responses to HIV proteins in different strains of mice. Additionally,there are some significant differences between the different viral
vectors for vaccination in CBA and BALB/c strains of mice.
4. Discussion
Assessment of an efficient prophylactic HIV vaccine involves
identifying broad immune responses to highly conserved HIV pro-
teins. The literature indicates that the majority of animal experi-
ments to evaluate immunogenicity have predominantly taken
place in mice with the preferred strain being C57BL/6. However
in our hands we found that in response to a ChAd vaccine with
Table 1
Number of possible epitopes binding H-2K alleles in CBA, C57BL/6 and BALB/c strains
of mice. Sequence data for the gag, pol 50 , nef and pol 30 transgenes were submitted to
the prediction binding program MAPPP (http://www.mpiib-berlin.mpg.de/mpiib-cgi/
MAPPP/binding) specifying mouse haplotype and peptide length. Binding scores
above 16 were tabulated against the strain of mouse for each transgene and each
vaccine vector.
Strain of mouse
CBA C57BL/6 BALB/c
Gag 14 7 26
Pol 50 12 18 22
Nef 8 3 18
Pol 30 29 6 48
S. Herath et al. / Vaccine 34 (2016) 4378–4385 4381HIV proteins, the C57BL/6 mice had a limited range of T cell
responses [9]. We therefore decided to determine whether there
were differences in the immune response to the HIV transgenes
with ChAd vaccination in different strains of mice.
We decided to use CBA, C57BL/6 and BALB/c mice as they have
different H-2K and H-2D restrictions with CBA mice being Kk and
Dk restricted, C57BL/6 being Kb and Db restricted, and BALB/c being
Kd and Dd restricted. Although this did not cover the whole range of
H-2 restrictions within the strains of mice, it did provide three dis-
tinct genetic backgrounds to test whether there were any differ-
ences in immune responses to the same HIV transgenes.
Furthermore, it provided the opportunity to determine whether
the vectors used in the vaccination protocol impacted on the
immune response.
Unsurprisingly, we found that the responses to the transgene
constituents were different between the strains of mice but inter-
estingly the C57BL/6 strain showed the most limited immune
response with ChAd3 or ChAd63 vectors. The broadest and highest
responses to the Gag, Pol 50 and Pol 30 were seen in the CBA and
BALB/c strain of mice (Figs. 1–4) and of these two strains, only
BALB/c mice responded to the nef transgene in both ChAd3 and
ChAd63 vaccinations (Fig. 4D).
The ability of CBA and BALB/c mice to respond so dynamically
to the transgene may in part be due to their haplotype restrictions.
Analysis of the predicted epitope binding data showed that both
CBA and BALB/c mice were able to bind 8-mer, 9-mer and 10-
mer peptides to H-2K while C57BL/6 mice were only predicted to
be able to bind 8-mer peptides. Indeed, structural analysis of the
different H-2K restrictions show that they bind peptides in differ-Pol 5' Nef
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Fig. 2. IFNc responses to mega pools in different strains of mice. CBA (grey bar and hor
(closed bar and right diagonal hatched bar) mice were vaccinated with either 1  108 IU o
were harvested and stimulated with the indicated mega pools. IFNc production was dete
**p < 0.01.ent regions resulting in different presentation to T cells [11–13].
This restriction in binding may result in lowered immune
responses to longer peptides in C57BL/6 mice which may be a
result of differential proteasomal processing. However, we did
not test this hypothesis using peptides of different lengths.
Furthermore, the ability of BALB/c mice to respond at a higher
magnitude to some peptide pools and also to the nef transgene
may, in part, be due to the fact that in addition to H-2K and H-
2D, BALB/c mice also have a third allele H-2L which CBA and
C57BL/6 mice do not (https://www.bdbiosciences.com/docu-
ments/mouse_alloantigens_chart.pdf). However, ChAd3 vaccinated
C57BL/6 mice, were able to respond to some peptide pools to the
nef transgene though the responses were very low, which suggests
that while the H-2L may confer some epitope binding of Nef pep-
tides it is not the only allele to do so. Speir et al. [14] have shown
that H-2Ld peptides show a similar binding anchorage to H-2Kb
(C57BL/6 mice) which suggests that the anchorage similarity may
bind similar peptides within Nef.
The lack of responses to the nef transgene in CBA mice may to
some extent be due to the dominant responses seen to the gag
and pol transgenes, which may mask the much lower responses
that may be present. However, the lack of Nef responses may be
detrimental following a viral challenge as Nef responses are shown
to be linked with lower viral loads [15]. It would have been inter-
esting to see if the CBA mice were able to mount responses to the
nef transgene in a single transgene vector, but this was, however,
beyond the scope of this study.
In addition to the H-2 restriction for class I, mice also have class
II alleles, I-A and I-E. While both CBA and BALB/c mice have both I-
A and I-E alleles, C57BL/6 mice only have I-A alleles. This suggests
that in C57BL/6 mice there may be limited class II presentation
which may influence CD4 T cell activation and CD4 T cell help
resulting in the lowered responses to HIV transgenes observed in
this strain of mice. Indeed, the importance of CD4 T cells in
immune responses and CD8 T cell activation is well documented
[16,17] and suggests that C57BL/6 mice may not be an ideal model
if CD4 T cell activation is required. Taken together, the absence of
the H-2L allele and the I-E allele in C57BL/6 mice may influence
antigen presentation of our HIV transgenes and may explain to
some extent the lowered IFNc responses detected compared to
the other two strains used in this study.
In addition to investigating the immune responses to HIV trans-
genes we also determined whether the vaccine vector influencedPol 3'
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Fig. 3. IFNc responses to Pol 50 peptide pools in different strains of mice. CBA (A), C57BL/6 (B) and BALB/c (C) mice were vaccinated with either 1  108 IU of either ChAd3-
GPN (black bar) or 1  109 IU ChAd63-GPN (grey bar). Splenocytes were harvested and stimulated with the indicated Pol 50 peptide pools. IFNc production was determined by
ELISpot and the graphs represent the mean of 3 mice ± SD. *p < 0.05.
4382 S. Herath et al. / Vaccine 34 (2016) 4378–4385the response in the different strains. We have previously shown
that in the C57BL/6 strain of mice there was no difference in IFNc
production between the two vectors, ChAd3 and ChAd63, when
dosing was normalised. However, we observed some significant
differences in responses to some peptide pools to the gag transgene
in CBA and BALB/c mice vaccinated with ChAd63. To have compa-
rable results between the two vectors in our C57BL/6 mouse
model, we had to inject a 10-fold higher concentration of ChAd63,
so these significant differences seen in the CBA and BALB/c mousemodel may be simply due to an increase in the vaccine vector.
Indeed, on analysis of the data for the gag transgene, most
responses to peptide pools were higher in the ChAd63 vaccinated
CBA and BALB/c animals though not all were significant. However,
analysis of the other transgenes showed that in CBA mice, there
were significant differences in some responses to the pol transge-
nes in ChAd3 vaccinated animals and no differences between the
vectors for BALB/c mice. Consequently the higher responses seen
in ChAd63 vaccinated animals cannot simply be explained by an
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Fig. 4. IFNc responses to Pol 30 and Nef peptide pools. CBA (A), C57BL/6 (B) and BALB/c (C and D) mice were vaccinated with either 1  108 IU of either ChAd3-GPN (black bar)
or 1  109 IU ChAd63-GPN (grey bar). Splenocytes were harvested and stimulated with the indicated Pol 30 (A–C) or Nef (D) peptide pools. IFNc production was determined
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S. Herath et al. / Vaccine 34 (2016) 4378–4385 4383increase in dose. As both vectors use the CAR receptor for entry
into cells [4] it is unlikely that receptor expression can solely
explain any differences observed. These results suggested that
immune responses to HIV proteins are dependent on a combina-
tion of the vector used, the transgene of interest and the haplotype
of the mouse model being employed. We have not statisticallyquantified the level and duration of expression of GPN from each
vector in the different mouse strains and expression of antigen
transcripts was seen by other investigators to vary between ChAd3
and 63 vectors expressing SIV-gag [18].
It has been shown previously that both ChAd3 and ChAd63
bearing a dominant HIV gag peptide induced a low frequency of
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Fig. 5. Heat map of IFNc responses to all peptide pools in different strains of mice. Results from Figs. 1 and 3–5 were collated into a heat map to show IFNc responses for each
strain of mouse either vaccinated with ChAd3 or ChAd63 against (A) Gag, (B) Pol 50 , (C) Pol 30 and (D) Nef peptide pools (PP). The colour scheme is shown and corresponds to
white as no response, light grey as less than 250 IFNc producing cells (SFC), grey as less than 500 SFC, dark grey as less than 1000 SFC and black as more than 1000 SFC.
4384 S. Herath et al. / Vaccine 34 (2016) 4378–4385IFNc only producing T cells but a high percentage of polyfunctional
T cells [1]. Our experiments did not include investigation of the
polyfunctionality of the responding cells. Furthermore, variation
of type I IFN responses between different rAd vectors was reported
and correlated to immunogenicity. Different mouse strains havebeen shown to produce different responses to pathogenic chal-
lenge and strain specific immunogenetic differences have been
described and were not limited to differences in MHC [19]. Indeed,
the innate immune response to the vaccine may have influenced
the IFNc response observed in our experiments. Sellers et al. [19]
S. Herath et al. / Vaccine 34 (2016) 4378–4385 4385discuss the differences in innate immune receptor complexes
between strains of mice and how they may influence the adaptive
response. An example is the expression of Killer cell lectin-like
receptors on NKT cells which are able to recognise MHC class I pep-
tide expression resulting in the production of IFNc and their
expression is highly divergent between strains of mice. Further-
more the authors identify that CBA and C57BL/6 mice have a Th1
bias to pathogens while BALB/c mice are TH2 biased. Taken
together, the differences observed in our study may be due to a
number of different factors such as innate immunity and MHC alle-
les and identifies the complexity between proteins and immune
responses.
Collating the data into a heat map helped to identify common
peptide pools between the three strains of mice and despite the
difference in haplotypes there were a limited number of common
peptide pools for some of the transgenes (Fig. 5). We did not deter-
mine the individual peptide within the common pools that the
strains of mice responded to so it is not possible to know if the dif-
ferent strains responded to the same peptide or a variety of pep-
tides present within the same pool.
Taken together our results showed that there were differences
in immune responses to the same transgenes between different
strains of mice and importantly that there were, in some cases, sig-
nificant differences in responses to different vectors in some
strains of mice. As C57BL/6 mice tend to be the mouse strain of
choice, our results suggested that we, along with other groups,
may have underestimated the potential of our vaccine candidate
due to lower immune responses. Dicks et al. [20] have shown that
that immune responses induced by ChAds differ between labora-
tory animals and a target species but this study has highlighted
the importance in the choice of mouse strain in determining
immune responses and that less than favourable results may not
be indicative of the product being tested but may be due to the
genetics of the mouse being employed.Conflict of interest
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